Funding
Gyros AB, which specialises in automated micro-immunoassays for developing protein drugs, has raised SEK 80 million (€7.5 million) in a fundraising led by SLS Invest, the leading shareholder.
The new funds will enable Gyros to drive the further commercialisation of its Gyrolab protein drug development technology. More than 20 companies worldwide, including Merck, Medimmune, GlaxoSmithKline, Amgen, Pfizer, Ablynx and ThromboGenics, currently use this system.
Following the financing, SLS Invest owns 88 per cent of Gyros.The financing was also supported by Industrifonden, which now has an 8 per cent stake.
Erik Walldén, CEO of Gyros, said the money will provide the resources needed to achieve profitability. “Our growing customer base, centred on leading companies developing new antibody and protein therapeutics, provides us with a strong platform [...]. We are now in a position to invest in the increased commercial resources needed to market [...] Gyrolab systems.”
Gyrolab reduces the time required to optimise and execute immunoassays. This results in increased efficiency in process development and in clinical evaluation of therapeutic proteins.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
